Anthropic’s Long-Term Benefit Trust appoints Vas Narasimhan to Board of Directors

Source: Anthropic Date: 2026-04-14 URL: https://www.anthropic.com/news/narasimhan-board

Summary

Anthropic’s Long-Term Benefit Trust — the independent governance body whose members hold no financial stake in Anthropic — appointed Vas Narasimhan, CEO of Novartis, to Anthropic’s Board of Directors. Narasimhan has overseen approval of more than 35 novel medicines under regulatory scrutiny and sits on the US National Academy of Medicine. With his appointment, Trust-appointed directors now constitute a Board majority, meaning independent oversight of the balance between commercial and public benefit interests formally outweighs shareholder-elected representation.

Implications

• Anthropic distribution machine thread. The Trust reaching Board majority is structurally significant ahead of Anthropic’s projected October 2026 IPO. Public company investors will scrutinize governance; a Board majority from a body with no financial stake and an explicit safety mandate is an unusual structure that Anthropic will need to explain to equity markets. Narasimhan’s regulated-industry background (FDA approval processes, post-market surveillance) gives the Trust representation with direct experience scaling consequential technology under institutional accountability.
• Enterprise deployment battleground thread. Anthropic’s enterprise pitch increasingly rests on governance credibility — particularly relevant after Murati’s testimony about OpenAI’s internal safety board being bypassed. A Board majority held by a fiduciary body with no commercial incentive is a differentiator enterprise procurement and legal teams can point to in vendor risk assessments. Narasimhan’s pharma background aligns with the financial services and legal verticals Anthropic is targeting.
• Watch: whether the Trust majority structure becomes a selling point in regulated-industry deals (healthcare, finance, legal), and how it is disclosed in the IPO S-1.